VVUS News 3.47 10/16/2014 06:00:54 Vivus Inc (VVUS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vivus Inc (VVUS) 3.47 $VVUS

Endo Buyout Of Auxilium Joins Two Changing Firms
at Investor's Business Daily - Thu Oct 09, 6:00PM CDT
Endo International inked a deal to buy fellow specialty drugmaker Auxilium Pharmaceuticals Thursday after raising its initial bid by nearly 20% to $2.6 billion in cash and stock, or $33.25 a share. Auxilium's shares rose 9% to 32.44, while Endo's...
ENDP: 60.19 (-0.91), VRX: 114.34 (-0.60), QLTI: 3.96 (-0.09), AUXL: 30.41 (-0.46), VVUS: 3.47 (+0.09)

Emergent BioSolutions Revamps Business to Drive Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 08, 4:50PM CDT
Emergent BioSolutions (EBS) has decided to restructure its operations.
MDVN: 89.63 (-1.68), EBS: 20.89 (+0.97), VVUS: 3.47 (+0.09), PDLI: 7.63 (+0.01)

3 Biotech Stocks Near 52-Week Lows Worth Buying
Motley Fool Staff - Motley Fool - Wed Oct 08, 7:35AM CDT
Source: Pixabay. While the broad-based SPDR S&P Biotech ETF has galloped higher by 20% year-to-date, a number of biotech stocks are wallowing near their 52-week lows. Could there be bargains to be had among this sea of red? With that in...
OREX: 3.98 (+0.52), VVUS: 3.47 (+0.09), NPSP: 24.93 (+1.83), ARNA: 3.83 (+0.21), EXEL: 1.55 (+0.03)

Halozyme's PEGPH20 Receives FDA Orphan Drug Designation - Analyst Blog
Kanchan Khanna - Zacks Investment Research - Tue Oct 07, 4:40PM CDT
Halozyme Therapeutics, Inc. (HALO) has gained orphan drug status for PEGPH20 for the treatment of pancreatic cancer.
HALO: 8.99 (+0.49), CBM: 16.91 (+0.58), VVUS: 3.47 (+0.09), LGND: 46.28 (+0.45)

Regeneron's Eye Drug Eylea Wins Another FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 3:30PM CDT
Regeneron's (REGN) Eylea has received FDA approval for treating RVO patients.
VVUS: 3.47 (+0.09), REGN: 334.75 (+6.68), PDLI: 7.63 (+0.01)

Newly Published Data Highlight the Effects of Weight Loss With Qsymia in Type 2 Diabetes
Marketwire - Mon Oct 06, 6:01AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced the publication of a paper examining study results that demonstrate the positive impact of weight loss with Qsymia® (phentermine and topiramate extended-release) capsules CIV (PHEN/TPM ER) plus lifestyle modification on glycemic control in subjects with type 2 diabetes.
VVUS: 3.47 (+0.09)

Is VIVUS Inc. a Short Sell?
George Budwell, The Motley Fool - Motley Fool - Sat Oct 04, 12:45PM CDT
Short selling is a high risk, high reward investing strategy that requires a rock-solid investing thesis to pull off successfully. Even then, short sellers often guess wrong and pay dearly in the form of a so-called "short squeeze." Healthcare and...
OREX: 3.98 (+0.52), AUXL: 30.41 (-0.46), VVUS: 3.47 (+0.09), ARNA: 3.83 (+0.21), NVS: 86.22 (-0.65)

VIVUS and Auxilium Announce Stendra Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 5:25PM CDT
VIVUS, Inc. (VVUS) and Auxilium Pharmaceuticals, Inc. (AUXL) announced that the FDA has approved Stendra's supplemental new drug application.
GILD: 96.16 (-1.02), AUXL: 30.41 (-0.46), VVUS: 3.47 (+0.09), AMGN: 130.90 (-1.30)

Nasdaq stocks posting largest volume increases
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CNQR: 127.19 (-0.50), ELOS: 8.44 (-0.09), EMKR: 5.58 (+0.15), EVBS: 6.10 (-0.08), MSON: 8.99 (-0.35), VVUS: 3.47 (+0.09), HSON: 3.35 (-0.26), RPRX: 10.08 (+0.45), PFBX: 13.24 (unch), MCHX: 3.89 (-0.08)

Most active Nasdaq-traded stocks
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
CNQR: 127.19 (-0.50), MU: 27.54 (+0.15), GILD: 96.16 (-1.02), FB: 73.21 (-0.38), VVUS: 3.47 (+0.09), MSFT: 43.22 (-0.51), INTC: 31.27 (-0.87), ZNGA: 2.28 (+0.01), AAPL: 97.54 (-1.21), CSCO: 22.96 (-0.10)

Oracle and Concur are big market movers
AP - Fri Sep 19, 3:40PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
DRC: 79.61 (-1.39), CLR: 53.85 (+1.11), CAG: 33.62 (+0.04), VVUS: 3.47 (+0.09), SNE: 17.04 (-0.01), JBLU: 10.30 (+0.07), COL: 74.10 (-0.20), ORCL: 38.30 (-0.16), RAD: 4.67 (-0.09), CNQR: 127.19 (-0.50), TIBX: 22.96 (-0.43), PIR: 12.32 (+0.20), RHT: 54.87 (+0.56), MCHX: 3.89 (-0.08)

3 Biotechs Investors Should Watch
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 12:49PM CDT
In the heathcare version of "Where the Money Is", guest Brian Orelli joins regulars Michael Douglass and David Williamson to discuss the state of the healthcare sector. In M&A news, Endo International has made an unsolicited bid to acquire ...
ZFGN: 17.66 (+1.15), OREX: 3.98 (+0.52), BIIB: 305.69 (+4.11), ACT: 217.24 (-4.83), ISIS: 38.97 (+2.13), AZN: 68.41 (-1.40), AUXL: 30.41 (-0.46), VVUS: 3.47 (+0.09), AMGN: 130.90 (-1.30), LLY: 62.87 (-0.27), ARNA: 3.83 (+0.21)

VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:32AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 12% on the day.
CBPO: 50.23 (+1.17), CBM: 16.91 (+0.58), GILD: 96.16 (-1.02), VVUS: 3.47 (+0.09)

Critical Alerts For FireEye, VIVUS, Ebix, 58.com and Walter Energy Released By InvestorsObserver
PR Newswire - Fri Sep 19, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, VVUS, EBIX, WUBA and WLT.
WUBA: 35.93 (+0.39), FEYE: 26.80 (+0.32), VVUS: 3.47 (+0.09), WLT: 1.78 (+0.17), EBIX: 13.47 (+0.46)

Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
PR Newswire - Fri Sep 19, 7:15AM CDT
BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA)
GILD: 96.16 (-1.02), AUXL: 30.41 (-0.46), VVUS: 3.47 (+0.09), LLY: 62.87 (-0.27), ARNA: 3.83 (+0.21), DOW: 44.09 (+0.16), CELG: 86.55 (+0.07), CELGZ: 3.52 (+0.09)

Market Maker Surveillance Report. MSON, VVUS, CNQR, PIP, CREG, CRRS, Winning Stocks With Lowest Price Friction For Thursday, September 18th 2014
M2 - Fri Sep 19, 4:02AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4944 companies with "abnormal" market making, 2520 companies with positive Friction Factors and 2350 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Misonix Inc (NASDAQ:MSON), Vivus Inc (NASDAQ:VVUS), Concur Technologies Inc (NASDAQ:CNQR), PharmAthene Inc (NYSE IP), China Recycling Energy Corp (NASDAQ:CREG), Corporate Resource Services Inc (OTC:CRRS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
CREG: 1.19 (unch), CNQR: 127.19 (-0.50), MSON: 8.99 (-0.35), PIP: 1.71 (-0.02), VVUS: 3.47 (+0.09), CRRS: 1.34 (+0.05)

Vivus Set to Possibly Pullback After Yesterday's Rally of 12.37%
Comtex SmarTrend(R) - Thu Sep 18, 4:16PM CDT
Vivus (NASDAQ:VVUS) traded in a range yesterday that spanned from a low of $4.21 to a high of $4.82. Yesterday, the shares gained 12.4%, which took the trading range above the 3-day high of $4.07 on volume of 34.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VVUS: 3.47 (+0.09)

Why VIVUS, Inc. Is Today's Best Biotech Stock
Sean Williams, The Motley Fool - Motley Fool - Thu Sep 18, 12:26PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of VIVUS , a biopharmaceutical company...
OREX: 3.98 (+0.52), AUXL: 30.41 (-0.46), VVUS: 3.47 (+0.09), ARNA: 3.83 (+0.21)

FDA OKs faster-acting label for ED drug Stendra
By The Associated Press - AP - Thu Sep 18, 11:21AM CDT
Federal regulators have approved a new label for Vivus' impotence drug, stating that it becomes effective in half the time that the previous label had stated.
AUXL: 30.41 (-0.46), PFE: 28.19 (-0.27), VVUS: 3.47 (+0.09)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stardock Fences 7 Targets Messy Windows Desktops Everywhere

Updated Category News Views 112

A cluttered Windows desktop is a tiny tax on attention, and Stardock has spent three decades selling people a way around it. Fences 7, released November 18, 2026, is the latest swing: a Windows 11-focused update that combines cosmetic polish with a genuinely practical privacy feature. This is not grand enterprise software, and nobody should pretend a $10 desktop utility...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 173

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!

Updated Category News Views 53

Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...

Continue Reading
Fox Hill Steel Marks a Long Public-Building Road Ahead

Updated Category News Views 54

A signed steel beam is a fine civic moment, but it is not the finish line. Burlington’s new Fox Hill Elementary School has reached its topping-off milestone, with the structural steel now in place for a 91,000-square-foot, two-story facility intended to serve roughly 325 kindergarten-through-fifth-grade students. That is tangible progress, the sort nobody can fake with...

Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 112

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading
Fapon’s Enzyme Push Meets Diagnostics Reality at AMP

Updated Category News Views 110

Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...

Continue Reading
Commodity Rout Tests a Market Already Short on Nerve

Updated Category News Views 24

Some weeks the tape merely wobbles; this one started throwing furniture. By midday Wednesday, traders were staring at sharp declines in gold, silver, crude and copper while the major equity benchmarks remained underwater for the week. That is an unpleasant combination. When growth-sensitive commodities and the usual hard-asset hiding places are all getting sold,...

Continue Reading
Pressure Injury Care Needs More Than Awareness Alone

Updated Category News Views 52

Wet skin does not care how polished the awareness campaign looks. That is the uncomfortable truth sitting underneath Worldwide Pressure Injury Prevention Day, the annual observance held on the third Thursday of November. Pressure injuries remain a stubborn problem across healthcare facilities and home care settings because prevention is not one tidy action; it is a chain...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 172

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 198

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading

Top 5 Most Recently Viewed Articles

Petrus Resources Announces Exciting Monthly Dividend Update

Updated Category News Views 239

Petrus Resources Monthly Dividend Declaration Petrus Resources Ltd. (TSX: PRQ) is excited to share that its Board of Directors has declared a new monthly dividend. This dividend is set at $0.01 per share and is designated for the shareholders of record. The scheduled payment date is set for December 30, and this announcement comes with important information for...

Continue Reading
Important Update for Sprinklr Investors: Know Your Rights

Updated Category News Views 100

Key Update for Sprinklr Investors Investors who have experienced losses exceeding $100,000 in Sprinklr, Inc. should take a moment to examine their rights as shareholders. Faruqi & Faruqi, LLP, a well-regarded national securities law firm, is currently investigating possible claims against Sprinklr, which is listed on the NYSE under the ticker CXM. The firm is available to...

Continue Reading
Collaborative Innovations in Multi-Omics Data Management

Updated Category News Views 167

DNAnexus and Panomics Unite for Biopharma Excellence In the ever-evolving landscape of biopharma, data plays a pivotal role in shaping advancements and innovations. DNAnexus, a leader in precision health data management, and Panomics, renowned for AI-powered omics data discovery, have announced a collaborative initiative aimed at revolutionizing how biopharma...

Continue Reading
WisdomTree Investors May Have Claims to Explore: Pomerantz Insights

Updated Category News Views 41

Pomerantz Investigates Potential Investor Claims Pomerantz LLP is currently investigating claims on behalf of investors of WisdomTree, Inc. (NYSE: WT). This investigation suggests a focus on the possibility of securities fraud or other unlawful business practices that may involve the Company's officers or directors. Insights on WisdomTree's Recent Challenges Recent...

Continue Reading
Introducing ROADSAVER: A Breakthrough in Carotid Stenting

Updated Category News Views 365

Announcing the ROADSAVER Carotid Stent System Terumo Interventional Systems (TIS) is thrilled to announce the early commercial availability of the ROADSAVER™ Carotid Stent System. This FDA-approved device is specifically designed for patients with carotid artery stenosis, aiming to reduce complications that may arise after carotid endarterectomy. With the integration of...

Continue Reading